127 related articles for article (PubMed ID: 2120080)
1. Non-tryptophan fluorescence and high molecular weight protein formation in lens crystallins of rats with chronic galactosemia: prevention by the aldose reductase inhibitor sorbinil.
Nagaraj RH; Monnier VM
Exp Eye Res; 1990 Oct; 51(4):411-8. PubMed ID: 2120080
[TBL] [Abstract][Full Text] [Related]
2. Suppression of pentosidine formation in galactosemic rat lens by an inhibitor of aldose reductase.
Nagaraj RH; Prabhakaram M; Ortwerth BJ; Monnier VM
Diabetes; 1994 Apr; 43(4):580-6. PubMed ID: 8138064
[TBL] [Abstract][Full Text] [Related]
3. Tissue-specific effects of aldose reductase inhibition on fluorescence and cross-linking of extracellular matrix in chronic galactosemia. Relationship to pentosidine cross-links.
Richard S; Tamas C; Sell DR; Monnier VM
Diabetes; 1991 Aug; 40(8):1049-56. PubMed ID: 1907247
[TBL] [Abstract][Full Text] [Related]
4. Sorbinil protection of lens protein components and cell hydration during diabetic cataract formation.
Beyer-Mears A; Cruz E; Nicolas-Alexandre J; Varagiannis E
Pharmacology; 1982; 24(3):193-200. PubMed ID: 6803262
[TBL] [Abstract][Full Text] [Related]
5. Retinal polyol and myo-inositol in galactosemic dogs given an aldose-reductase inhibitor.
Kern TS; Engerman RL
Invest Ophthalmol Vis Sci; 1991 Dec; 32(13):3175-7. PubMed ID: 1748548
[TBL] [Abstract][Full Text] [Related]
6. Discordant effects of the aldose reductase inhibitor, sorbinil, on vascular structure and function in chronically diabetic and galactosemic rats.
Tilton RG; Pugliese G; LaRose LS; Faller AM; Chang K; Province MA; Williamson JR
J Diabet Complications; 1991; 5(4):230-7. PubMed ID: 1779018
[TBL] [Abstract][Full Text] [Related]
7. The effects of aldose reductase inhibition on nerve sorbitol and myoinositol concentrations in diabetic and galactosemic rats.
Yue DK; Hanwell MA; Satchell PM; Handelsman DJ; Turtle JR
Metabolism; 1984 Dec; 33(12):1119-22. PubMed ID: 6438438
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the effects of Zopolrestat and Sorbinil on lens myo-inositol influx.
Beyer-Mears A; Diecke FP; Mistry K; Cruz E
Pharmacology; 1997 Feb; 54(2):76-83. PubMed ID: 9088040
[TBL] [Abstract][Full Text] [Related]
9. Aldose reductase inhibition fails to prevent retinopathy in diabetic and galactosemic dogs.
Engerman RL; Kern TS
Diabetes; 1993 Jun; 42(6):820-5. PubMed ID: 8495805
[TBL] [Abstract][Full Text] [Related]
10. Prevention or moderation of some ultrastructural changes in the RPE and retina of galactosemic rats by aldose reductase inhibition.
Vinores SA; Campochiaro PA
Exp Eye Res; 1989 Sep; 49(3):495-510. PubMed ID: 2507341
[TBL] [Abstract][Full Text] [Related]
11. Permeability changes in blood-retinal barrier of galactosemic rats are prevented by aldose reductase inhibitors.
Lightman S; Rechthand E; Terubayashi H; Palestine A; Rapoport S; Kador P
Diabetes; 1987 Nov; 36(11):1271-5. PubMed ID: 3117606
[TBL] [Abstract][Full Text] [Related]
12. Increases in collagen type IV and laminin in galactose-induced retinal capillary basement membrane thickening--prevention by an aldose reductase inhibitor.
Das A; Frank RN; Zhang NL; Samadani E
Exp Eye Res; 1990 Mar; 50(3):269-80. PubMed ID: 2108050
[TBL] [Abstract][Full Text] [Related]
13. Effects of the aldose reductase inhibitor sorbinil on the isolated cultured rat lens.
Yeh LA; Rafford CE; Beyer TA; Hutson NJ
Metabolism; 1986 Apr; 35(4 Suppl 1):4-9. PubMed ID: 3083208
[TBL] [Abstract][Full Text] [Related]
14. The effects of hyperbaric oxygen on the crystallins of cultured rabbit lenses: a possible catalytic role for copper.
Padgaonkar VA; Leverenz VR; Fowler KE; Reddy VN; Giblin FJ
Exp Eye Res; 2000 Oct; 71(4):371-83. PubMed ID: 10995558
[TBL] [Abstract][Full Text] [Related]
15. Prevention of naphthalene-1,2-dihydrodiol-induced lens protein modifications by structurally diverse aldose reductase inhibitors.
Sato S; Sugiyama K; Lee YS; Kador PF
Exp Eye Res; 1999 May; 68(5):601-8. PubMed ID: 10328974
[TBL] [Abstract][Full Text] [Related]
16. Reversal of stage-I sugar cataract by Sorbinil, an aldose reductase inhibitor.
Beyer-Mears A; Cruz E; Varagiannis E
Pharmacology; 1985; 31(2):88-96. PubMed ID: 3927328
[TBL] [Abstract][Full Text] [Related]
17. Properties of novel aldose reductase inhibitors, M16209 and M16287, in comparison with known inhibitors, ONO-2235 and sorbinil.
Kato K; Nakayama K; Mizota M; Miwa I; Okuda J
Chem Pharm Bull (Tokyo); 1991 Jun; 39(6):1540-5. PubMed ID: 1934175
[TBL] [Abstract][Full Text] [Related]
18. Aldose reductase inhibitors and prevention of galactose cataracts in rats.
Unakar N; Tsui J; Johnson M
Invest Ophthalmol Vis Sci; 1989 Jul; 30(7):1623-32. PubMed ID: 2545646
[TBL] [Abstract][Full Text] [Related]
19. Galactose cataract prevention with sorbinil, an aldose reductase inhibitor: a light microscopic study.
Datiles M; Fukui H; Kuwabara T; Kinoshita JH
Invest Ophthalmol Vis Sci; 1982 Feb; 22(2):174-9. PubMed ID: 6799419
[TBL] [Abstract][Full Text] [Related]
20. The effects of sorbinil, an aldose reductase inhibitor, on the corneal endothelium in galactosemic dogs.
Datiles MB; Kador PF; Kashima K; Kinoshita JH; Sinha A
Invest Ophthalmol Vis Sci; 1990 Nov; 31(11):2201-4. PubMed ID: 2122961
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
